方達控股(01521.HK)斥5.6億元收購加州合同研究機構公司Quintara Discovery
方達控股(01521.HK)公佈,以代價最高爲7,200萬美元(約5.59億港元)收購Quintara Discovery全部股權。該公司在美國加州註冊成立,提供合同研究機構服務,包括向製藥、生物科技、醫療器械或診斷行業提供體外吸收、分佈、代謝及排泄分析、生物分析服務,以及化驗開發及化合物篩選服務。
公司認爲,通過訂立合併協議,合併將擴大集團在提供發現以及吸收、分佈、代謝及排泄(ADME)分析服務的能力,並將使集團得以把握在美國西岸(公司目前市場覆蓋範圍有限的地區)的增長機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.